StifelAfter two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
ADVERTISEMENT
After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.